Legato Capital Management LLC Increases Stock Holdings in Repligen Corporation (NASDAQ:RGEN)

Legato Capital Management LLC increased its stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 101.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,000 shares of the biotechnology company's stock after purchasing an additional 8,060 shares during the period. Legato Capital Management LLC's holdings in Repligen were worth $2,036,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in RGEN. KBC Group NV boosted its position in shares of Repligen by 14.9% in the first quarter. KBC Group NV now owns 2,544 shares of the biotechnology company's stock worth $324,000 after purchasing an additional 329 shares during the period. LPL Financial LLC lifted its position in Repligen by 47.6% during the fourth quarter. LPL Financial LLC now owns 32,237 shares of the biotechnology company's stock valued at $4,873,000 after purchasing an additional 10,395 shares during the last quarter. Signaturefd LLC raised its stake in shares of Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 124 shares during the period. GAMMA Investing LLC raised its stake in shares of Repligen by 40.1% in the first quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company's stock valued at $122,000 after acquiring an additional 274 shares during the period. Finally, Zions Bancorporation N.A. increased its stake in Repligen by 48.9% in the 4th quarter. Zions Bancorporation N.A. now owns 14,079 shares of the biotechnology company's stock worth $2,027,000 after buying an additional 4,626 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Price Performance

NASDAQ RGEN traded down $0.13 on Friday, hitting $121.74. The company had a trading volume of 950,629 shares, compared to its average volume of 754,837. The company has a market capitalization of $6.84 billion, a PE ratio of -270.53, a PEG ratio of 2.27 and a beta of 1.11. The company's fifty day moving average price is $123.58 and its 200-day moving average price is $137.45. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.79 and a quick ratio of 5.79. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The company had revenue of $169.17 million for the quarter, compared to analysts' expectations of $163.65 million. During the same quarter in the previous year, the company posted $0.28 EPS. The firm's quarterly revenue was up 10.4% on a year-over-year basis. As a group, analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Wall Street Zen downgraded shares of Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Canaccord Genuity Group lowered their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a report on Wednesday, April 16th. Stephens upgraded shares of Repligen to an "overweight" rating and set a $160.00 target price for the company in a research note on Tuesday. HC Wainwright reissued a "buy" rating and set a $180.00 price target on shares of Repligen in a research report on Monday, May 5th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Repligen presently has a consensus rating of "Moderate Buy" and a consensus price target of $169.92.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.